Spesolimab increases the percentage of generalized pustular psoriasis (GPP) patients with clear skin over time as measured by the Physician’s Global Assessment for GPP (GPPGA): Results from the EFFISAYIL® 2 trial. (2024). SKIN The Journal of Cutaneous Medicine, 8(6), s490. https://doi.org/10.25251/skin.8.supp.490